MiraBiologics Inc.

News archive

January 27, 2020InformationNEW
Feb 8 [Japanese Only] Broadcasting (Part 2) will be scheduled in which President Kato will appear at BS Fuji “konokuninoyukusue2 (every Saturday from 18:00 to 18:30)” .
January 27, 2020InformationNEW
Feb 1 [Japanese Only] Broadcasting (Part 1) will be scheduled in which President Kato will appear at BS Fuji“konokuninoyukusue2 (every Saturday from 18:00 to 18:30)” .
January 17, 2020InformationNEW
Jan. 15: Notice Concerning Third Party Allocation / In order to further accelerate the business, MiraBiologics Inc. announces the completion of 550 million Japanese Yen (US$ 5 Million, as of Jan. 10, 2020) private financing, led by Shinsei Capital Partners Ltd. as a lead investor, and , SMBC Venture Capital Co., Ltd, SBI Investment Co., Ltd.
January 10, 2020InformationNEW
Nov. 28: At the “Forbes JAPAN CEO Conference” hosted by Forbes JAPAN, we received the “Mizuho Award”, a special award at the “Japanese Entrepreneurs Ranking” award ceremony (PDF attached, Japanese only).
January 10, 2020InformationNEW
Nov. 14: We assented Kanagawa Prefectural Tama High School’s Super Science High school (SSH) initiative and accepted Tama High School’s company visit as an SDGs initiative. (attached to PDF, Japanese only).
January 10, 2020InformationNEW
Oct. 11: A patent for which an exclusive license agreement concluded with the University of Tokyo and Osaka University was registered in Japan (Patent No. 6598344). We are continuing the transition to each country.
January 10, 2020InformationNEW
Sep. 20: Ms. Mihara of Osaka University Takagi Laboratory, our joint research partner, gave a presentation on LassoGraft Technology at the 92nd Annual Meeting of the Biochemical Society of Japan, Symposium “New Biopharmaceutical Innovation from Japan,” (PDF attached, Japanese only).
June 17, 2019Information
Jun 23 (Sun) 15:00, Prof. Junichi Takagi had a talk session at the 5th Workshop on “Industrial Development and Structural Biology” in Kobe.
March 27, 2019Information
We renewed our website.
December 20, 2018Information
Our Company entered into a sublicense agreement with PeptiDream Inc. (TSE First Section: Securities Code 4587) concerning a part of the patent for the drug discovery platform system: PDPS (Peptide Discovery Platform System) technology.